Expert Opinion on Drug Metabolism & Toxicology

Article	Citations
Probing the mechanism of reduced in vivo potency of insulin detemir	139
A three-arm clinical study to compare pharmacokinetic and pharmacodynamic similarity of the denosumab biosimilar LY06006 with reference denosumab in healthy male subjects	60
The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update	55
Comorbidities and the right dose: antipsychotics	55
A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database	54
Pharmacotherapy in kidney disease: what it takes to move from general guidance to specific recommendations to stratified subgroups of patients - the tale of autosomal dominant polycystic kidney diseas	38
Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis	36
The Central Role of Cytochrome P450 Reductase (CPR) in Hyperoxic Lung Injury	34
Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata	31
Drug metabolizing enzymes and transporters, and their roles for the development of drug-induced liver injury	31
Guidance for interactions between antiseizure medications	26
Hormones, microbes, and PrEP drugs in the female genital tract	26
Tirabrutinib–anthracycline interactions in the brain tumor microenvironment: a focus on metabolic inactivation and resistance	26
Therapeutic drug monitoring of letermovir in allogeneic hematopoietic cell transplant recipients: where are we?	26
Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine	25
Bioactivity descriptors for in vivo toxicity prediction: now and the future	25
Immune-mediated liver injury caused by immune checkpoint inhibitors exhibits distinct clinical features that differ from autoimmune hepatitis	25
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer	24
Pharmacokinetic evaluation of concizumab for the treatment of hemophilia	23
A comprehensive review of the efficacy and safety of ertugliflozin	21
Correction	20
In NAMs we trust – an innovative paradigm-shift in risk-based chemicals management for globally harmonized protection goals	19
Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in vigibase	19
Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury	18
Impact of sex and gender medicine on antibiotic research and use: a narrative review of existing evidence	18

Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update	18
Population pharmacokinetics of olanzapine in pediatric patients with psychiatric disorders	17
The safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T mutation, supports a Phase 1/2 clinical study	17
Pharmacokinetic considerations surrounding triple therapy for uncontrolled asthma	17
Potential integration of multiple organs-on-a-chip for comprehensive drug–drug interaction prediction	16
Drug-drug interactions between psychotropic medications and oral contraceptives	16
Respiratory aspiration during treatment with benzodiazepines, antiepileptic and antidepressant drugs in the pharmacovigilance database from VigiBase	15
Clinical pharmacokinetics of antipsychotics in pediatric populations: a scoping review focusing on dosing regimen	15
Development and hepatotoxicity of rifamycin derivatives	15
Pharmacokinetic evaluation of aripiprazole monohydrate as a once every 2-months long-acting injectable antipsychotic for schizophrenia	15
Physiologically based pharmacokinetic modeling in obesity: applications and challenges	14
A high-throughput liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of p -cresol sulfate, p -cresol	14
Pharmacokinetic considerations surrounding the use of levetiracetam for seizure prophylaxis in neurocritical care – an overview	14
Clinical pharmacokinetics and pharmacodynamics of nicardipine; a systematic review	14
Clinically significant interactions between drugs, microbiome, and sex	13
Drug absorption from oral formulations in patients with short bowel syndrome: a comprehensive update of the literature	13
Risk factors and prediction for DILI in clinical practice	13
Current state-of-the-art approaches for mass spectrometry in clinical toxicology: an overview	13
The use of glucarpidase as a rescue therapy for high dose methotrexate toxicity – a review of pharmacological and clinical data	13
Pregnancy and epilepsy: pharmacokinetic insights into antiseizure medications	13
Recent progress in machine learning approaches for predicting carcinogenicity in drug development	13
Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review	12
Development and application of a population pharmacokinetic model repository for caffeine dose tailoring in preterm infants	12
PBPK models of the female reproductive tract: current and future analysis	12
Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes	12
Population pharmacokinetic–pharmacodynamic analysis of givinostat	12
Bioequivalence of generic and branded ibrutinib capsules in healthy Chinese volunteers under fasting and fed conditions: a randomized, four-period, fully replicated, crossover study	12
Practical perspectives on addressing hepatotoxicity during clinical candidate selection	12
Rivaroxaban vs. apixaban in short bowel syndrome: a focused clinical pharmacology review	12
Rezafungin acetate for the treatment of candidemia and invasive candidiasis: a pharmacokinetic evaluation	12
Understanding pharmacokinetic variability in women across different life stages	12
In-silico approaches to assessing multiple high-level drug-drug and drug-disease adverse drug effects	12
CYP3A inhibitor itraconazole affect pharmacokinetic behavior of famitinib and its active metabolite: results of a single-center, single-arm, open-label and fixed sequence study	12
Interactions between phytotherapeutics and chemotherapeutics: the current evidence	11
Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarction	11
Optimizing antibiotic dosing regimens for nosocomial pneumonia: a window of opportunity for pharmacokinetic and pharmacodynamic modeling	10
Lessons learned from aldehyde dehydrogenases as non-P450 aldehyde-oxidizing enzymes: implications for the ‘exposome’ and human health	10
Safety of concomitant use of oral anticoagulants and antidiabetic drugs: a systematic review of observational studies	10
Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis	10
Switching from cangrelor to oral P2Y 12 inhibitors: a focused review on drug–drug interactions	10
Overcoming barriers to machine learning applications in toxicity prediction	10
Clinical pharmacokinetics of levodopa and relevant add-on therapies for Parkinson’s disease	10
Pharmacokinetics of apixaban in patients with short bowel syndrome: a Bayesian re-estimation approach	10
Analysis of drug–drug interactions in patients with HIV and metabolic syndrome	10
Identification of genetic biomarkers associated with pharmacokinetics and pharmacodynamics of apixaban in Chinese healthy volunteers	10
Pharmacokinetic and pharmacodynamic alterations in older people: what we know so far	9
Cardiomyocyte-specific CYP2J2 and its therapeutic implications	9
Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids	9
Recent progress in adverse events of carboxylic acid non-steroidal anti-inflammatory drugs (CBA-NSAIDs) and their association with the metabolism: the consequences on mitochondrial dysfunction and oxi	9
Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healt	9

The oral GnRH antagonists, a new class of drugs in gynecology: from pharmacokinetics to possible clinical applications	9
Drug interactions in people with HIV treated with antivirals for other viral illnesses	9
Machine learning and deep learning approaches for enhanced prediction of hERG blockade: a comprehensive QSAR modeling study	9
Drug dosing optimization in critically ill children under continuous renal replacement therapy: from basic concepts to the bedside model informed precision dosing	9
Interactions between antiepileptic drugs and direct oral anticoagulants for primary and secondary stroke prevention	9
An update on the pharmacokinetic and pharmacodynamic interactions between antidepressants and antiseizure medications	9
CYP2D6 pharmacogenetics and phenoconversion in personalized medicine	9
Toxic metabolites and metabolic soft spots of celastrol based on glutathione metabolic capture and high-resolution mass spectrometry	9
Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications	9
DILI prediction in drug development: present and future	8
Drug-drug interactions in metastatic hormone-sensitive prostate cancer (mHSPC): practical considerations for treating men with androgen receptor pathway inhibitors and common medications in this stage	8
Regulation of cyclophosphamide induced hepatotoxicity by REV-ERBα modifiers	8
Pharmacokinetic studies in dialysis-dependent patients: limited data availability	8
Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout	8
The influence of pharmacodynamics and pharmacokinetics on the antimigraine efficacy and safety of novel anti-CGRPergic pharmacotherapies: a narrative review	8
Mechanism-based drug safety testing using innovative in vitro liver models: from DILI prediction to idiosyncratic DILI liability assessment	8
Psychedelics, psychiatry and pharmacokinetics - where are we now?	8
Drug–drug interactions in HIV-infected patients receiving chemotherapy	8
Considerations for drug–drug interactions between long-acting antiretrovirals and immunosuppressants for solid organ transplantation	8
Intraocular drugs: pharmacokinetic strategies and the influence on efficacy and durability	8
Important roles of transporters in the pharmacokinetics of anti-viral nucleoside/nucleotide analogs	7
The impact of menstrual cycle on the pharmacokinetics of antiseizure medications and lithium: a systematic review and meta-analysis	7
Acetaminophen toxicity and overdose: current understanding and future directions for NAC dosing regimens	7
Strategies for the treatment of acute benzodiazepine toxicity in a clinical setting: the role of antidotes	7
Optimizing drug therapy during pregnancy: a spotlight on population pharmacokinetic modeling	7
How can we better address the pharmacokinetics of antipsychotics in children and adolescents?	7
From pharmacokinetic genes to polygenic scores and multi-omic integration: advances toward precision psychiatry	7
A comparative study on the consistency of different decision support software systems from the perspective of potential drug–drug interactions in intensive care unit patients	7
Interindividual variability in statin pharmacokinetics and effects of drug transporters	7
Genetic variation in organic cation transporters and considerations in drug development	7
Efficacy, safety and tolerability of drugs for alopecia: a comprehensive review	7
Cardiometabolic complications in children and adolescents with HIV on antiretroviral therapy	7
Metabolic and toxicological considerations of Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma	7
A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens	7
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it?	7
Understanding the impact of ABCG2 polymorphisms on drug pharmacokinetics: focus on rosuvastatin and allopurinol	7
Cefepime/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation	7
Paternal exposure to antiseizure medications and offspring outcomes: a systematic review and meta-analysis of observational studies	6
In vitro neurotoxicity testing: lessons from chemotherapy-induced peripheral neurotoxicity	6
Transporters and drug secretion into human breast milk	6
Pharmacokinetic drug evaluation of co-packaged sulbactam for injection and durlobactam for injection for the treatment of Acinetobacter baumannii-calcoaceticus	6
Pharmacokinetic considerations for drugs that treat diarrhea-predominant irritable bowel syndrome: what’s new?	6
Evaluation of the role of comedication properties in the severity of drug-induced liver injury using machine learning techniques	6
Drug-drug interactions in patients living with HIV who undergo solid organ transplant	6
The impact of sepsis on hepatic drug metabolism in critically ill patients: a narrative review	6
Cannabidiol: metabolism and clinical efficacy in epileptic patients	6
A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database	6
Pharmacokinetic characteristics of risperidone ISM for the treatment of schizophrenia	6
Pharmacokinetic review of janus kinase inhibitors and its clinical implications for the management of rheumatoid arthritis	6
Pharmacogenomic and inflammatory determinants of antipsychotic-induced extrapyramidal toxicity in Egyptian patients with schizophrenia	6
The evolving serotonin syndrome spectrum: from acute syndrome to smoldering presentations and personalized risk management	6
Dose optimization of β-lactam antibiotics in children: from population pharmacokinetics to individualized therapy	6
Pharmacokinetics and safety of the combination of KL130008 and methotrexate in rheumatoid arthritis patients: a multicenter, open-label phase Ib trial	6
Benzodiazepines and clozapine co-prescription in clinical practice: a systematic review and expert recommendations	6
Cephalosporins with warfarin increase the risk of bleeding: myth or fact?	6
Screening tools to evaluate the neurotoxic potential of botanicals: building a strategy to assess safety	6
Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer	6
Lessons learned from the influence of CYP2C9 genotype on warfarin dosing	6
The influence of female sex and estrogens on drug pharmacokinetics: what is the evidence?	6
In silico prediction of drug-induced nephrotoxicity: current progress and pitfalls	6
A critical review of methotrexate clinical interactions: role of transporters	6
Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes	6
Pharmacokinetic evaluation of ibrexafungerp for the treatment of vulvovaginal candidiasis and beyond	6
A novel in vivo approach to monitoring Cyp3a induction and inhibition by bioluminescent urinalysis	6
Suboptimal concentrations of isavuconazole in critically ill patients treated for mold infections: a population pharmacokinetic analysis	5
Sex-specific UGT expression and function: prevalence, potential mechanisms and significance	5
Improving on in-silico prediction of oral drug bioavailability	5
Assessing DDI risks in drug discovery and development: approaches, challenges, and trends	5
The mysteries of target site concentrations of antibiotics in bone and joint infections: what is known? A narrative review	5
What is the most effective and safest Non-steroidal anti-inflammatory drug for treating osteoarthritis in patients with comorbidities?	5
Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody–drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach	5
A repeat-dose toxicity study of human umbilical cord mesenchymal stem cells in NOG mice by intravenous injection	5
ADME investigations of novel therapeutic modalities: challenges and opportunities 2025	5
Pharmacokinetic evaluation of sofosbuvir/velpatasvir for the treatment of Chronic Hepatitis C in pediatrics aged 3 and older	5
Evaluating the pharmacokinetic and pharmacodynamic impact of different modes of ticagrelor administration	5
Sex-gender differences in pharmacokinetics	5
Comparison of pharmacokinetic properties of alteplase and tenecteplase. The future of thrombolysis in acute ischemic stroke	5
Milvexian, a novel factor XIa inhibitor for stroke prevention: pharmacokinetic and pharmacodynamic evaluation	5
Impact of pediatric continuous renal replacement therapy parameters on meropenem, piperacillin, and tazobactam pharmacokinetics: an in vitro model	4
Predicting the potential for organic cation transporter 1-mediated drug–drug interactions with fenoterol by amitriptyline, fluoxetine, selegiline, metformin, and verapamil	4

Combined oral contraceptives and pharmacokinetic drug interactions: impact on efficacy and safety	4
Current and future physiologically based pharmacokinetic (PBPK) modeling approaches to optimize pharmacotherapy in preterm neonates	4
Effects of obesity on the pharmacology of proton pump inhibitors: current understanding and future implications for patient care and research	4
Post-marketing pharmacovigilance of tedizolid: emerging safety signals	4
Pharmacokinetics and pharmacodynamics of angiogenesis inhibitors used to treat cervical cancer: current and future	4
Diagnosing idiosyncratic drug-induced liver injury: lessons from monocyte-derived hepatocyte-like cells	4
Pharmacokinetic evaluation of bictegravir + emtricitabine + tenofovir alafenamide in HIV treatment	4
Pharmacokinetics, pharmacodynamics, safety, and tolerability of dopamine-receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting	4
Safety of medicines during breastfeeding – from case report to modeling: a contribution from the ConcePTION project	4
The relationship between CYP2C9 gene polymorphisms and azilsartan metabolism in vitro	4
Comparison of ADMET profile between thiosemicarbazide and semicarbazide derivatives regarding anticancer properties	4
JAK1 inhibitors for the treatment of atopic dermatitis: a focus on pharmacokinetic considerations	4
Epigenetics is involved in the pleiotropic effects of statins	4
Modeling drug-induced liver injury: current status and future prospects	4
Metabolic and toxicological considerations regarding CGRP mAbs and CGRP antagonists to treat migraine in COVID-19 patients: a narrative review	4
Preventable serious drug-disease interactions of reserve antibiotics	4
The clinical implication of inflammation-driven regulation of drug-metabolizing enzymes	4
Where developmental toxicity meets explainable artificial intelligence: state-of-the-art and perspectives	4
Microbiome-driven PKs: addressing research gaps and shaping future directions beyond the narrative review	4
What is the impact of metabolic dysfunction–associated steatotic liver disease on drug transport and metabolism?	4
Substrate-specificity of pharmacogenomic variability – clinical relevance and emerging predictive strategies	4